PDCD1 and melanoma: The aim of this register-based study from Denmark, focusing on high-risk melanoma patients treated with adjuvant anti-PD-1, was to investigate the prognostic value of immune-related adverse events, the spleen-to-liver ratio, and the bone marrow-to-liver ratio detected by [18F]FDG-PET/CT.